QuintilesIMS leading Big Pharma firms in oncology collaboration
According to the contract research organization (CRO), there is currently a lack of information and inconsistencies in knowledge surrounding the “real-world use” of oncology products in Europe.
The new collaboration seeks to address this issue and to ultimately provide a clearer picture of how anti-cancer treatment are used in the everyday.
"Oncology is a major human and economic burden for European healthcare systems," Sally Beatty, a company spokesperson from Pfizer, told Outsourcing-Pharma.com.
"We believe that the data gaps are complex and the topic is so important that a collective approach, encompassing the expertise of range of industry leaders, will allow for a more robust, comprehensive and complete evidence-based resource that will benefit the EU healthcare systems and, ultimately, patients."
Specifically, the companies will look into how oncology products are used by patient type, and with what sequences and combinations of therapies, and in which indications.
QuintileIMS explained that the initiative is “intended to provide more timely, consistent and comprehensive data resources that could be used to provide further insight for healthcare systems to make better informed decisions on patient care in the future.”
Earlier this week QuintilesIMS also reported that is has has agreed to purchase TKL Research’s Clinical Trials Division (CTD), which will become a part of Novella Clinical, a Quintiles company.
Both announcements follow Quintiles' completed merger with IMS Health, which became official last month.
The merger was initially announced in May of this year, with new senior management roles announced in late August.
